Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


08.04.2019

1 BMC Cancer
1 Br J Dermatol
1 Br J Haematol
3 Haematologica
1 J Biol Chem
2 J Clin Oncol
5 Lancet Oncol
5 Leuk Lymphoma
1 Leukemia
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. SCHORB E, Finke J, Ihorst G, Kasenda B, et al
    Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
    BMC Cancer. 2019;19:287.
    PubMed     Text format     Abstract available


    Br J Dermatol

  2. GOYAL A, Goyal K, Bohjanen K, Pearson D, et al
    Epidemiology of primary cutaneous gamma/delta T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma in the United States from 2006-2015: A Surveillance, Epidemiology, and End Results-18 analysis.
    Br J Dermatol. 2019 Apr 5. doi: 10.1111/bjd.17985.
    PubMed     Text format     Abstract available


    Br J Haematol

  3. BURKART M, Schieber M, Basu S, Shah P, et al
    Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma.
    Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15889.
    PubMed     Text format     Abstract available


    Haematologica

  4. BELLEI M, Federico M
    The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project.
    Haematologica. 2019;104:e178.
    PubMed     Text format    

  5. KUMAR A, Ying Z, Alperovich A, Dogan A, et al
    Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.
    Haematologica. 2019;104:e163-e166.
    PubMed     Text format    

  6. DREGER P
    Comment to "The outcome of peripheral T-cell lymphoma patients failing first-line therapy".
    Haematologica. 2019;104:e178.
    PubMed     Text format    


    J Biol Chem

  7. ZOU J, Li W, Misra A, Yue F, et al
    Correction: The viral restriction factor Tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with Beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy.
    J Biol Chem. 2019;294:5211.
    PubMed     Text format    


    J Clin Oncol

  8. LEONARD JP
    De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Apr 2:JCO1900445. doi: 10.1200/JCO.19.00445.
    PubMed     Text format    

  9. BARTLETT NL, Wilson WH, Jung SH, Hsi ED, et al
    Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
    J Clin Oncol. 2019 Apr 2:JCO1801994. doi: 10.1200/JCO.18.01994.
    PubMed     Text format     Abstract available


    Lancet Oncol

  10. DAVIES A, Cummin TE, Barrans S, Maishman T, et al
    Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2019 Apr 1. pii: S1470-2045(18)30935.
    PubMed     Text format     Abstract available

  11. REID JH, Marini BL, Nachar VR, Devata S, et al
    PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma.
    Lancet Oncol. 2019;20:e188.
    PubMed     Text format    

  12. MESGUICH C, Milpied N, Hindie E
    PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma.
    Lancet Oncol. 2019;20:e189.
    PubMed     Text format    

  13. CASASNOVAS RO, Bouabdallah R, Brice P, Lazarovici J, et al
    PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.
    Lancet Oncol. 2019;20:e190.
    PubMed     Text format    

  14. JARDIN F
    Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge.
    Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30021.
    PubMed     Text format    


    Leuk Lymphoma

  15. SORIGUE M, Bishton M, Domingo-Domenech E, McMillan A, et al
    Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594212.
    PubMed     Text format     Abstract available

  16. AYOUB Z, Andraos T, Milgrom SA, Pinnix CC, et al
    Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.
    Leuk Lymphoma. 2019 Apr 3:1-9. doi: 10.1080/10428194.2019.1597081.
    PubMed     Text format     Abstract available

  17. BICCLER JL, Savage KJ, Brown PDN, Jorgensen J, et al
    Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594219.
    PubMed     Text format     Abstract available

  18. LIU J, Hong J, Ahn KS, Go J, et al
    ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
    Leuk Lymphoma. 2019 Apr 5:1-9. doi: 10.1080/10428194.2019.1594211.
    PubMed     Text format     Abstract available

  19. UMINO K, Fujiwara SI, Ikeda T, Kawaguchi SI, et al
    Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Apr 5:1-8. doi: 10.1080/10428194.2018.1564824.
    PubMed     Text format     Abstract available


    Leukemia

  20. PAPIN A, Tessoulin B, Bellanger C, Moreau A, et al
    CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0463.
    PubMed     Text format     Abstract available


    PLoS One

  21. LINABURG T, Davis AR, Frey NV, Khawaja MR, et al
    Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia.
    PLoS One. 2019;14:e0215021.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: